DalsnaFinance

AbbVie is buying a biotech company working on an experimental eczema drug for $10.9 billion

Stocks MarketWatch By MarketWatch 20 Jun 2026 16:11 1 min read
AbbVie is buying a biotech company working on an experimental eczema drug for $10.9 billion

AbbVie is buying a biotech company working on an experimental eczema drug for $10.9 billion  MarketWatch

AbbVie is buying a biotech company working on an experimental eczema drug for $10.9 billion MarketWatch

Read the full story on MarketWatch → Opens the original article on news.google.com

Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.